TRVI

13.4352.08%
JV

James V. Cassella

Chief Development Officer

Dr. James V. Cassella, also known as Jim, Ph.D., is Chief Development Officer of Trevi Therapeutics, Inc. from September 27, 2024 and had been its Director since February 13, 2020 until September 30, 2024 and was its Independent Director from February 13, 2020 to September 2024. Dr. Cassella serves as Chief Development Officer of Sun Pharmaceutical Industries Inc., a publicly traded biotechnology company, since March 2023 and he previously served as Chief Development Officer of Concert Pharmaceuticals, Inc., a publicly traded biotechnology company, from February 2015 until it was acquired by Sun Pharmaceutical Industries Inc. in March 2023. Dr. Cassella served as the Chief Scientific Officer and Executive Vice President of Research & Development at Alexza Pharmaceuticals, Inc. from July 26, 2012 to January 30, 2015. Dr. Cassella served as Senior Vice President of Research & Development at Alexza Pharmaceuticals, Inc. since June 2004 until July 2012. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company, including Senior Vice President of Clinical Research & Development from January 2003 to June 2004 and Vice President since 1999. Dr. Cassella served as an Assistant Professor of Neuroscience at Oberlin College. Dr. Cassella has years of experience in drug development, including experience with product development, clinical trial design and execution, regulatory affairs and product registration in the US and EU. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a Postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and a B.A. degree in Psychology from the University of New Haven.

Positions